Half-dose apixaban noninferior for preventing recurrent VTE in cancer patients
For patients with active cancer and venous thromboembolism, a reduced dose of apixaban is noninferior to the standard dose for preventing recurrent thromboembolic episodes and significantly reduces the risk of clinically relevant bleeding, report the API-CAT investigators.
